| Title |
Evaluation of Persistence of Resistant Variants with Ultra-Deep Pyrosequencing in Chronic Hepatitis C Patients Treated with Telaprevir
|
|---|---|
| Published in |
PLOS ONE, July 2012
|
| DOI | 10.1371/journal.pone.0041191 |
| Pubmed ID | |
| Authors |
Xiomara V. Thomas, Joep de Bruijne, James C. Sullivan, Tara L. Kieffer, Cynthia K. Y. Ho, Sjoerd P. Rebers, Michel de Vries, Hendrik W. Reesink, Christine J. Weegink, Richard Molenkamp, Janke Schinkel |
| Abstract |
Telaprevir, a hepatitis C virus NS3/4A protease inhibitor has significantly improved sustained viral response rates when given in combination with pegylated interferon alfa-2a and ribavirin, compared with current standard of care in hepatitis C virus genotype 1 infected patients. In patients with a failed sustained response, the emergence of drug-resistant variants during treatment has been reported. It is unclear to what extent these variants persist in untreated patients. The aim of this study was to assess using ultra-deep pyrosequencing, whether after 4 years follow-up, the frequency of resistant variants is increased compared to pre-treatment frequencies following 14 days of telaprevir treatment. |
Mendeley readers
The data shown below were compiled from readership statistics for 33 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 3% |
| Brazil | 1 | 3% |
| Unknown | 31 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 27% |
| Student > Ph. D. Student | 7 | 21% |
| Other | 4 | 12% |
| Student > Master | 3 | 9% |
| Student > Doctoral Student | 2 | 6% |
| Other | 6 | 18% |
| Unknown | 2 | 6% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 13 | 39% |
| Medicine and Dentistry | 8 | 24% |
| Biochemistry, Genetics and Molecular Biology | 3 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Immunology and Microbiology | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 5 | 15% |